Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jun;29(6):759–762. doi: 10.1111/j.1365-2125.1990.tb03698.x

Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine.

D K Robbins 1, P J Wedlund 1, R Kuhn 1, R J Baumann 1, R H Levy 1, S L Chang 1
PMCID: PMC1380179  PMID: 2116161

Abstract

The effect of valproic acid (VPA) on the disposition of carbamazepine-10,11-epoxide (epoxide) was studied in five epileptic patients on chronic carbamazepine (CBZ) therapy. The individual pharmacokinetic parameters influencing epoxide disposition were determined in the presence and absence of VPA. VPA significantly decreased the clearance of unbound epoxide (an in vivo index of epoxide hydrolase activity), but did not appear to affect epoxide formation. VPA also increased the free concentrations of both CBZ and epoxide.

Full text

PDF
759

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodie M. J., Forrest G., Rapeport W. G. Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol. 1983 Dec;16(6):747–749. doi: 10.1111/j.1365-2125.1983.tb02257.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eichelbaum M., Tomson T., Tybring G., Bertilsson L. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. Clin Pharmacokinet. 1985 Jan-Feb;10(1):80–90. doi: 10.2165/00003088-198510010-00004. [DOI] [PubMed] [Google Scholar]
  3. Kerr B. M., Rettie A. E., Eddy A. C., Loiseau P., Guyot M., Wilensky A. J., Levy R. H. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther. 1989 Jul;46(1):82–93. doi: 10.1038/clpt.1989.110. [DOI] [PubMed] [Google Scholar]
  4. Levy R. H., Moreland T. A., Morselli P. L., Guyot M., Brachet-Liermain A., Loiseau P. Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia. 1984 Jun;25(3):338–345. doi: 10.1111/j.1528-1157.1984.tb04198.x. [DOI] [PubMed] [Google Scholar]
  5. McKauge L., Tyrer J. H., Eadie M. J. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit. 1981;3(1):63–70. [PubMed] [Google Scholar]
  6. Mendez-Alvarez E., Soto-Otero R., Sierra-Marcuño G. The effect of storage conditions on the stability of carbamazepine and carbamazepine-10,11-epoxide in plasma. Clin Chim Acta. 1986 Feb 15;154(3):243–246. doi: 10.1016/0009-8981(86)90039-2. [DOI] [PubMed] [Google Scholar]
  7. Pisani F., Fazio A., Oteri G., Spina E., Perucca E., Bertilsson L. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide. Br J Clin Pharmacol. 1988 May;25(5):611–613. doi: 10.1111/j.1365-2125.1988.tb03354.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Robbins D. K., Chang S. L., Baumann R. J., Wedlund P. J. Quantitation of trans-10,11-dihydroxy-10,11-dihydrocarbamazepine in human urine by high-performance liquid chromatography. J Chromatogr. 1987 Mar 20;415(1):208–213. doi: 10.1016/s0378-4347(00)83212-0. [DOI] [PubMed] [Google Scholar]
  9. Tomson T., Tybring G., Bertilsson L. Single-dose kinetics and metabolism of carbamazepine-10,11-epoxide. Clin Pharmacol Ther. 1983 Jan;33(1):58–65. doi: 10.1038/clpt.1983.8. [DOI] [PubMed] [Google Scholar]
  10. Tybring G., von Bahr C., Bertilsson L., Collste H., Glaumann H., Solbrand M. Metabolism of carbamazepine and its epoxide metabolite in human and rat liver in vitro. Drug Metab Dispos. 1981 Nov-Dec;9(6):561–564. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES